OncoMyx was founded on breakthrough research demonstrating the myxoma virus is highly immuno-interactive and can selectively infect and kill a broad range of cancer cell types. As a virus that is nonpathogenic to humans, myxoma does not have to overcome pre-existing immunity. With a large genome, myxoma is ideal for multi-arming, creating a precision medicine approach with a unique oncolytic virus that activates the cancer immunity cycle and expands the therapeutic effectiveness of immunotherapies.